AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful deve ...

TORONTO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it has rescheduled its November 6, 2025 earnings conference call to discuss the results for the third quarter ended September 30, 2025. The call will still be held on Thursday, November 6, 2025, but will take place at 8:30 a.m. Eastern Time. The Company will report its financial results for the third quarter 2025 on the same d ...

CALGARY, Alberta, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based, internationally focused energy transition company working in Central Asia is pleased to announce it has finished drilling the vertical portion of its first well in Uzbekistan (the “First Well”) to a total depth of 2805 meters. The initial portion of the First Well was drilled as a vertical pilot to penetrate and evaluate currently producing carbonate reservoir sections as well as ...

Core Insights - Heartflow, Inc. has introduced the Heartflow PCI Navigator, an AI-driven tool designed to enhance percutaneous coronary interventions (PCI) planning by providing interventional cardiologists with a patient-specific 3D model that integrates anatomy, plaque composition, and lesion-specific physiology [1][16] - The PLAN CALCIUM study will present data at the TCT 2025 conference, demonstrating how AI-powered plaque analysis can influence decisions in managing highly calcified lesions during PCI [6][2] - The NAVIGATE-PCI registry will enroll approximately 2,500 patients across 30 sites to evaluate the impact of CT-guided PCI planning on physician confidence, procedural safety, and patient outcomes [8][9] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), with a focus on transforming how clinicians manage care through innovative solutions backed by extensive clinical evidence [10][15] - The company has developed a proprietary data pipeline from over 110 million annotated CTA images, which supports its AI-driven solutions and has been validated in over 100 studies involving more than 365,000 patients [10] - Heartflow's technology is designed to provide actionable insights into plaque location, volume, and composition, facilitating early detection and accurate diagnosis of CAD [15] Product Features - The PCI Navigator integrates essential measurements, including IVUS-like and FFR-like visualizations, into a seamless web-based interface, streamlining the decision-making process in the cath lab [3][5] - The tool enhances planning by allowing interventional cardiologists to review and input data on anatomy, plaque, and lesion-specific physiology before procedures, addressing the information gap that often exists prior to PCI [4][5] - The technology aims to improve efficiency and clinical confidence for both patients and healthcare staff by consolidating necessary information into one intuitive view [5][4] Research and Development - The PLAN CALCIUM study highlights the potential of combining Heartflow Plaque Analysis with coronary CTA imaging and FFRCT analysis, showing that over half of the lesions had altered plans for calcium modification due to AI insights [6][7] - The NAVIGATE-PCI registry is set to begin in 2026, aiming to assess the broader clinical use of PCI Navigator and its impact on interventional practice and patient care [8][9]

Real-Time Tracking, Escape Alerts, and a Community-Powered Pet Finding Network Work Together to Unleash Unmatched Peace of Mind SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Life360 now serves everyone’s favorite family member! The leading family connection and safety company today announced Life360 Pet GPS, the first pet tracker specifically designed to fit the lives of today’s connected families. The device also unlocks new features in the Life360 app, advancing the platform to become the first whole- ...

Core Insights - Synergy CHC Corp. announced significant retail authorizations and distribution partnerships to expand its FOCUSfactor supplements and FOCUSfactor Focus + Energy beverages in the U.S., Canada, and international markets, responding to rising consumer demand for clean energy and cognitive health products [1][7]. U.S. Expansion - Kroger will launch three FOCUSfactor SKUs across 1,600 locations starting April 2026, enhancing FOCUSfactor's position as a leader in cognitive health supplements [2]. - Wakefern Food Corp. will introduce five FOCUSfactor Focus + Energy SKUs in 365 retail locations, furthering Synergy's national beverage rollout strategy [3]. Canadian Expansion - Uniprix will launch FOCUSfactor supplement SKUs in 300 stores beginning February 2026, while Fortinos will debut FOCUSfactor Focus + Energy beverages in 24 locations [4]. - Pilot Flying J will carry FOCUSfactor beverages across 56 travel centers, marking a significant milestone in Synergy's retail expansion in Canada [5]. International Expansion - PriceSmart will launch FOCUSfactor Focus + Energy 12-pack across 47 clubs in 13 countries, reaching over 3 million members, thus introducing FOCUSfactor beverages to new markets in Latin America and the Caribbean [6]. Strategic Partnerships - The partnerships with major retailers like Kroger, Wakefern, and PriceSmart validate Synergy's global scaling strategy and commitment to delivering clean energy and brain health solutions [7].

Core Insights - NANO Nuclear Energy Inc. has completed the acquisition of Global First Power Limited, enhancing its position as a leading developer of microreactors in North America [1][4][11] - The acquisition provides NANO Nuclear with direct ownership of the regulatory licensing application for the KRONOS MMR™ Energy System demonstration project in Canada, facilitating progress in the licensing process [2][5] - NANO Nuclear aims to advance its KRONOS MMR™ technology through concurrent licensing and construction programs in both the U.S. and Canada, establishing a strong North American footprint [6][8] Acquisition Details - The acquisition allows NANO Nuclear to continue from a strong foundation, benefiting from GFPL's previous regulatory engagements and progress, particularly in the Vendor Design Review and early LTPS submission [5][9] - NANO Nuclear's assumption of a liability of approximately $640,000 owed by GFPL to the Canadian Nuclear Safety Commission is a principal consideration of the acquisition [9] Strategic Positioning - The acquisition is seen as a defining moment for NANO Nuclear, unifying its North American development strategy and enabling rapid advancement in both licensing and construction [6][8] - NANO Nuclear is now positioned to deploy advanced microreactors in both the U.S. and Canada, marking a significant step towards establishing a leadership role in the microreactor market [6][9] Project Development - Concurrently, NANO Nuclear has initiated site preparation activities for its project at the University of Illinois Urbana-Champaign, with a milestone ceremony scheduled to highlight ongoing work [7] - The company is focused on expanding access to clean, reliable, and decentralized power through its microreactor projects, which include the KRONOS MMR™, ZEUS™, and LOKI MMR™ [8][12]

Company earns “Best” ranking in Arizona, California, Nevada, North Carolina and Texas, reflecting strong performance in care quality, prevention and satisfaction U.S. News & World Report Names Alignment Health Plan a “Best” Medicare Advantage Insurance Company in Five States U.S. News & World Report names Alignment Health Plan a 2026 Best Insurance Company for Medicare Advantage in all five states where it operates: Arizona, California, Nevada, North Carolina, and Texas. ORANGE, Calif., Oct. 22, 2025 (GL ...

Core Viewpoint - Madrigal Pharmaceuticals, Inc. is set to release its third-quarter 2025 financial results on November 4, 2025, before the U.S. financial markets open [1] Group 1: Financial Results Announcement - The financial results will be followed by a live webcast hosted by Madrigal's management at 8 a.m. Eastern Time [2] - Participants are encouraged to register at least 15 minutes prior to the webcast for a timely connection [2] Group 2: Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's medication, Rezdiffra (resmetirom), is the first and only FDA and European Commission approved treatment for MASH with moderate to advanced fibrosis (F2 to F3) [3] - An ongoing Phase 3 outcomes trial is assessing Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [3]

SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding in the Compan ...